drugset / Trial / NCT00724009

Clofarabine Bone Marrow Cytoreduction

NCT00724009

NaSingle-groupOpen-labelTreatment

Summary

For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.

Timeline

Start
2007-12
Primary completion
2010-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 30 mg/m2 Intravenous

Indications